Stay updated with breaking news from Seppo Yl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This month marks 15 years since PLOS ONE published its first papers. As we celebrate this milestone, we invited authors of some of the first papers to be published, as well as an author of a more recent paper, to share information about their careers, their perspectives on Open Science, and their experiences as PLOS ONE authors.
E-Mail IMAGE: The researchers analysed the contribution of the five main cell types involved in coronary artery disease. view more Credit: UEF/Raija Törrönen Using single cell technology, a new study sheds light on the significance of genetic risk factors for, and the diversity of cells involved in, the development of coronary artery disease. The researchers analysed human atherosclerotic lesions to map the chromatin accessibility of more than 7,000 cells. The chromatin accessibility is known to reflect active regions and genes in the genome. The findings were published in Circ...
Researchers at the University of Eastern Finland have uncovered potential mechanisms by which microRNAs (miRNA) drive atherogenesis in a cell-type-specific manner. Published in the Arteriosclerosis, Thrombosis, and Vascular Biology journal, the study provides novel insight into the miRNA profiles of the main cell types involved in atherosclerosis.
New technologies are expected to enhance nasal vaccines industry growth as particular attention is being paid to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that will benefit from the mucosal route of delivery. Key challenges for the nasal vaccines industry includes translating in vivo data to clinical outcomes
State support for a Finnish Covid nasal spray comes up short. Finnish nasal spray vaccine firm continues its search for investors. Image: Janne Järvinen / Yle A Finnish Covid vaccine company says it risks private investors withdrawing from the endeavour after the state investment agency Business Finland said it would not cover the full cost of a clinical trial. In April, Rokote Laboratories Finland, the company that developed the vaccine, applied for a grant from the public financier that would have covered 80 percent of the costs of the vaccine’s test phases. Private funders had tentativ...